The global digital biomarkers market size was accounted for USD 4.11 billion in 2024, grew to USD 5.04 billion in 2025 and is predicted to surpass around USD 31.82 billion by 2034, representing a healthy CAGR of 22.71% between 2025 and 2034. The North America digital biomarkers market size was calculated at USD 2.40 billion in 2024 and is expected to grow at a fastest CAGR of 22.73% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Digital Biomarkers Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Digital Biomarkers Market, by System Component Type, 2025-2034
8.1.1. Data Collection Tools
8.1.1.1. Market Revenue and Forecast (2022-2034)
8.1.2. Data Integration Systems
8.1.2.1. Market Revenue and Forecast (2022-2034)
9.1. Digital Biomarkers Market, by Application, 2025-2034
9.1.1. Sleep & Movement Disease
9.1.1.1. Market Revenue and Forecast (2022-2034)
9.1.2. Cardiovascular Diseases
9.1.2.1. Market Revenue and Forecast (2022-2034)
9.1.3. Respiratory Disease
9.1.3.1. Market Revenue and Forecast (2022-2034)
9.1.4. Neurodegenerative Disorders
9.1.4.1. Market Revenue and Forecast (2022-2034)
9.1.5. Diabetes
9.1.5.1. Market Revenue and Forecast (2022-2034)
9.1.6. Gastrointestinal Disease
9.1.6.1. Market Revenue and Forecast (2022-2034)
9.1.7. Psychiatric Disorder
9.1.7.1. Market Revenue and Forecast (2022-2034)
9.1.8. Others
9.1.8.1. Market Revenue and Forecast (2022-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by System Component (2022-2034)
10.1.2. Market Revenue and Forecast, by Application (2022-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by System Component (2022-2034)
10.1.3.2. Market Revenue and Forecast, by Application (2022-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by System Component (2022-2034)
10.1.4.2. Market Revenue and Forecast, by Application (2022-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by System Component (2022-2034)
10.2.2. Market Revenue and Forecast, by Application (2022-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by System Component (2022-2034)
10.2.3.2. Market Revenue and Forecast, by Application (2022-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by System Component (2022-2034)
10.2.4.2. Market Revenue and Forecast, by Application (2022-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by System Component (2022-2034)
10.2.5.2. Market Revenue and Forecast, by Application (2022-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by System Component (2022-2034)
10.2.6.2. Market Revenue and Forecast, by Application (2022-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by System Component (2022-2034)
10.3.2. Market Revenue and Forecast, by Application (2022-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by System Component (2022-2034)
10.3.3.2. Market Revenue and Forecast, by Application (2022-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by System Component (2022-2034)
10.3.4.2. Market Revenue and Forecast, by Application (2022-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by System Component (2022-2034)
10.3.5.2. Market Revenue and Forecast, by Application (2022-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by System Component (2022-2034)
10.3.6.2. Market Revenue and Forecast, by Application (2022-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by System Component (2022-2034)
10.4.2. Market Revenue and Forecast, by Application (2022-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by System Component (2022-2034)
10.4.3.2. Market Revenue and Forecast, by Application (2022-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by System Component (2022-2034)
10.4.4.2. Market Revenue and Forecast, by Application (2022-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by System Component (2022-2034)
10.4.5.2. Market Revenue and Forecast, by Application (2022-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by System Component (2022-2034)
10.4.6.2. Market Revenue and Forecast, by Application (2022-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by System Component (2022-2034)
10.5.2. Market Revenue and Forecast, by Application (2022-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by System Component (2022-2034)
10.5.3.2. Market Revenue and Forecast, by Application (2022-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by System Component (2022-2034)
10.5.4.2. Market Revenue and Forecast, by Application (2022-2034)
11.1. Bayer AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Biogen Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. ActigraphLLc
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Amgen Inc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Fitbit Inc
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. GlaxoSmithKline Plc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Koninklijke Philips N.V.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Mindstrong Health
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Medical Care Corporation
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample